Who Paid My Doc
Voraxaze
Drug Toxicity Antidote (Methotrexate Toxicity)
NDC 50633-210-11
General payments
$1,609,425
Research payments
$1,606,738
Through program year 2024, $1,609,425 in general payments and $1,606,738 in research payments were reported against Voraxaze (Toxicity Antidote (Methotrexate Toxicity)).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
8 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | General | $425,149 | 265 |
| 2024 | Research | $291,528 | 5 |
| 2023 | General | $266,044 | 262 |
| 2023 | Research | $463,806 | 6 |
| 2022 | General | $596,660 | 198 |
| 2022 | Research | $285,632 | 8 |
| 2021 | General | $321,572 | 128 |
| 2021 | Research | $565,772 | 9 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2024.
The top 5 of 24 specialties; each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.
The top 5 of 29 states; each share is of general payments naming this product in 2024 where a state was reported.
Records
853 general · 28 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.